Skip to Content

Anixa Biosciences Inc ANIX

Morningstar Rating
$3.59 +0.03 (0.84%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ANIX is trading at a 13% discount.
Price
$3.60
Fair Value
$7.92
Uncertainty
Very High
1-Star Price
$8.96
5-Star Price
$2.91
Economic Moat
Lbnfx
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ANIX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$3.56
Day Range
$3.503.70
52-Week Range
$2.756.45
Bid/Ask
$3.59 / $4.07
Market Cap
$113.85 Mil
Volume/Avg
75,682 / 233,507

Key Statistics

Price/Earnings (Normalized)
Price/Sales
631.36
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
6

Comparables

Valuation

Metric
ANIX
ANAB
CLDX
Price/Earnings (Normalized)
Price/Book Value
5.484.926.95
Price/Sales
631.3640.81392.22
Price/Cash Flow
Price/Earnings
ANIX
ANAB
CLDX

Financial Strength

Metric
ANIX
ANAB
CLDX
Quick Ratio
11.8910.638.46
Current Ratio
12.5010.928.84
Interest Coverage
−8.53
Quick Ratio
ANIX
ANAB
CLDX

Profitability

Metric
ANIX
ANAB
CLDX
Return on Assets (Normalized)
−19.10%−22.03%−31.80%
Return on Equity (Normalized)
−19.80%−61.38%−34.51%
Return on Invested Capital (Normalized)
−24.50%−56.21%−34.11%
Return on Assets
ANIX
ANAB
CLDX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRMhtv$550.2 Bil
VRTX
Vertex Pharmaceuticals IncPbrszw$111.1 Bil
REGN
Regeneron Pharmaceuticals IncNhpkw$107.7 Bil
MRNA
Moderna IncLvzq$36.9 Bil
ARGX
argenx SE ADRCrv$24.2 Bil
BNTX
BioNTech SE ADRYfnww$22.3 Bil
ALNY
Alnylam Pharmaceuticals IncGqwnps$19.9 Bil
BMRN
Biomarin Pharmaceutical IncXmpjtnp$17.2 Bil
RPRX
Royalty Pharma PLC Class AWhznf$13.9 Bil
INCY
Incyte CorpXvppxxb$13.6 Bil

Sponsor Center